Cetrotide
Company: Asta Medica
Approval Status: Approved August 2000
Treatment for: For the prevention of premature ovulation in women undergoing controlled ovarian stimulation
Areas: Endocrinology; Obstetrics/Gynecology
| General Information | Clinical Results | Side Effects | Mechanism of Action | Additional Information |
General Information
Cetrotide has been developed to prevent premature ovulation in women undergoing controlled ovarian stimulation for assisted reproductive technologies (ART). Cetrotide blocks the effects of a natural hormone, called gonadotropin-releasing hormone (GnRH). GnRH controls the secretion of another hormone, called luteinizing hormone (LH), which induces ovulation during the menstrual cycle. During hormone treatment for ovarian stimulation, premature ovulation may lead to eggs that are not suitable for fertilization. Cetrotide blocks such undesirable premature ovulation.
Clinical Results
The effectiveness of Cetrotide has been examined in five clinical trials (two phase II and three phase III trials). Two dose regimens were investigated in these trials: either a single dose per treatment cycle or multiple dosing. In the phase II studies, a single dose of 3 mg was established as the minimal effective dose for the inhibition of premature LH surges with a protection period of at least four days. When Cetrotide is administered in a multidose regimen, 0.25 mg was established as the minimal effective dose. The extent and duration of LH-suppression was found to be dose dependent.
In the phase III program, efficacy of the single 3 mg dose regimen and the multiple 0.25 mg dose regimen was established separately in two controlled studies utilizing active comparitors. A third non-comparative study evaluated only the multiple 0.25 mg dose regimen of Cetrotide.
In the five phase II and phase III trials, 184 pregnancies have been reported out of a total of 732 patients (including 21 pregnancies following the replacement of frozen-thawed embryos). No drug related allergic reactions were reported from these clinical studies. (from FDA Label)
Side Effects
Adverse effects associated with Cetrotide include (but are not limited to) the following:
- Reddening, itching, or swelling at injection site
- Nausea
- Headache
Additionally, Cetrotide should not be used by individuals who are or may be pregnant.
Mechanism of Action
GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels.
Cetrotide competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. The onset of LH suppression is approximately one hour with the 3 mg dose and two hours with the 0.25 mg dose. This suppression is maintained by continuous treatment and there is a more pronounced effect on LH than on FSH. An initial release of endogenous gonadotropins has not been detected with Cetrotide, which is consistent with an antagonist effect. (from FDA Label)
Additional Information
For further information on Cetrotide, please visit the web site of Asta Medica
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
